Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$91.01 -0.1%	$70.63	$52.50 ▼ $92.53	$1.97B	0.61	737,724 shs	432,200 shs
BEAM Beam Therapeutics	$16.64 +3.9%	$18.74	$13.52 ▼ $35.25	$1.68B	2.22	2.49 million shs	2.39 million shs
CRLBF Cresco Labs	$1.24 +3.4%	$0.67	$0.43 ▼ $1.82	$606.65M	1.42	1.85 million shs	1.33 million shs
VCEL Vericel	$37.03 +4.5%	$38.95	$33.09 ▼ $63.00	$1.87B	1.27	604,556 shs	758,535 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	-0.14%	+4.05%	+36.04%	+57.48%	+48.35%
BEAM Beam Therapeutics	+3.94%	-6.62%	-24.91%	-1.13%	-34.72%
CRLBF Cresco Labs	+3.42%	+25.74%	+103.81%	+86.38%	-32.04%
VCEL Vericel	+4.49%	+2.07%	-8.23%	-9.51%	-23.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIP ANI Pharmaceuticals	3.1651 of 5 stars	1.6	1.0	3.3	2.5	3.3	1.3
BEAM Beam Therapeutics	2.2369 of 5 stars	3.5	0.0	0.0	2.7	2.5	0.6
CRLBF Cresco Labs	0.7068 of 5 stars	0.0	3.0	0.0	3.2	0.0	0.6
VCEL Vericel	2.4811 of 5 stars	3.5	0.0	0.0	3.6	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	3.10	Buy	$84.75	-6.88% Downside
BEAM Beam Therapeutics	3.07	Buy	$48.45	191.19% Upside
CRLBF Cresco Labs	3.00	Buy	N/A	N/A
VCEL Vericel	3.00	Buy	$60.33	62.93% Upside

Current Analyst Ratings Breakdown

Latest CRLBF, ANIP, VCEL, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	ANIP ANI Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/11/2025	ANIP ANI Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$65.00 ➝ $77.00
8/8/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $93.00
8/8/2025	ANIP ANI Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$94.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
8/1/2025	VCEL Vericel	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $58.00
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$84.00
6/16/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00
6/3/2025	CRLBF Cresco Labs	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Moderate Buy

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$614.38M	3.21	$7.60 per share	11.98	$20.13 per share	4.52
BEAM Beam Therapeutics	$63.52M	26.50	N/A	N/A	$10.35 per share	1.61
CRLBF Cresco Labs	$724.34M	0.84	N/A	N/A	$0.74 per share	1.67
VCEL Vericel	$237.22M	7.88	$0.31 per share	118.50	$6.08 per share	6.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	-$18.52M	-$0.77	N/A	21.62	N/A	-1.37%	25.03%	8.00%	N/A
BEAM Beam Therapeutics	-$376.74M	-$4.50	0.00	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
CRLBF Cresco Labs	-$74.44M	-$0.13	0.00	N/A	N/A	-6.67%	-11.77%	-3.22%	N/A
VCEL Vericel	$10.36M	$0.12	308.61	84.16	N/A	2.85%	2.47%	1.69%	11/6/2025 (Estimated)

Latest CRLBF, ANIP, VCEL, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	ANIP ANI Pharmaceuticals	$1.42	$1.80	+$0.38	$0.36	$187.18 million	$211.37 million
8/7/2025	Q2 2025	CRLBF Cresco Labs	-$0.04	-$0.05	-$0.01	-$0.05	$162.00 million	$163.62 million
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	-$0.01	+$0.03	-$0.01	$64.61 million	$63.24 million
5/30/2025	Q1 2025	CRLBF Cresco Labs	-$0.03	-$0.04	-$0.01	-$0.04	$164.37 million	$165.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CRLBF Cresco Labs	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	1.39	2.54	1.96
BEAM Beam Therapeutics	N/A	6.75	6.75
CRLBF Cresco Labs	1.33	3.10	2.22
VCEL Vericel	N/A	4.97	4.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
BEAM Beam Therapeutics	99.68%
CRLBF Cresco Labs	0.05%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	11.10%
BEAM Beam Therapeutics	3.50%
CRLBF Cresco Labs	N/A
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	600	21.70 million	19.29 million	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
CRLBF Cresco Labs	2,900	491.02 million	N/A	Not Optionable
VCEL Vericel	300	50.46 million	47.84 million	Optionable

CRLBF, ANIP, VCEL, and BEAM Headlines

Recent News About These Companies

Vanguard Group Inc. Purchases 7,978 Shares of Vericel Corporation $VCEL

August 23 at 3:35 AM | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Buy" by Brokerages

August 23 at 3:24 AM | marketbeat.com

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 98,005 Shares of Vericel Corporation $VCEL

August 20 at 9:12 AM | marketbeat.com

Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating

August 20 at 4:35 AM | msn.com

11 Best Small-Cap Growth Stocks to Buy Right Now

August 19, 2025 | insidermonkey.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Lord Abbett & CO. LLC

August 19, 2025 | marketbeat.com

Public Sector Pension Investment Board Grows Holdings in Vericel Corporation (NASDAQ:VCEL)

August 18, 2025 | marketbeat.com

Invesco Ltd. Acquires 35,345 Shares of Vericel Corporation (NASDAQ:VCEL)

August 18, 2025 | marketbeat.com

LPL Financial LLC Has $2.92 Million Holdings in Vericel Corporation (NASDAQ:VCEL)

August 18, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Stock Position Reduced by Neuberger Berman Group LLC

August 17, 2025 | marketbeat.com

Townsquare Capital LLC Purchases 7,312 Shares of Vericel Corporation (NASDAQ:VCEL)

August 13, 2025 | marketbeat.com

Vericel (VCEL) Receives a Buy from Canaccord Genuity

August 12, 2025 | theglobeandmail.com

Global Alpha Capital Management Ltd. Boosts Stock Holdings in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

Zions Bancorporation National Association UT Makes New Investment in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

CenterBook Partners LP Invests $888,000 in Vericel Corporation (NASDAQ:VCEL)

August 9, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Mutual of America Capital Management LLC

August 8, 2025 | marketbeat.com

Vericel Q2 Revenue Jumps 20%

August 5, 2025 | fool.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Geneva Capital Management LLC

August 4, 2025 | marketbeat.com

FY2025 EPS Estimates for Vericel Decreased by Analyst

August 4, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Short Interest Update

August 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRLBF, ANIP, VCEL, and BEAM Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$91.01 -0.13 (-0.14%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$91.15 +0.14 (+0.15%)

As of 08/22/2025 06:29 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Beam Therapeutics NASDAQ:BEAM

$16.64 +0.63 (+3.94%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$16.71 +0.07 (+0.42%)

As of 08/22/2025 07:57 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Cresco Labs OTCMKTS:CRLBF

$1.24 +0.04 (+3.42%)

As of 08/22/2025 03:58 PM Eastern

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.

Vericel NASDAQ:VCEL

$37.03 +1.59 (+4.49%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$37.03 +0.00 (+0.01%)

As of 08/22/2025 05:54 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time